Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Loma Linda University11 enrolled

Overview

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Melanoma Kidney Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center * Patients must sign and give written informed consent in accordance with institutional and federal guidelines Exclusion Criteria: * Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Locations (1)

Loma Linda University Cancer Center

Beaumont, California, United States

Outcomes

Primary Outcomes

LAK cytotoxicity

Time frame: 4 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.